Wee1 kinase as a target for cancer therapy

Khanh Do, James H. Doroshow, Shivaani Kummar

Research output: Contribution to journalReview articlepeer-review

149 Scopus citations

Abstract

Wee1, a protein kinase, regulates the G2 checkpoint in response to DNA damage. Preclinical studies have elucidated the role of wee1 in DNA damage repair and the stabilization of replication forks, supporting the validity of wee1 inhibition as a viable therapeutic target in cancer. MK-1775, a selective and potent small-molecule inhibitor of wee1, is under clinical development as a potentiator of DNA damage caused by cytotoxic chemotherapies. We present a review of the role of wee1 in the cell cycle and DNA replication and summarize the clinical development to date of this novel class of anticancer agents.

Original languageEnglish (US)
Pages (from-to)3348-3353
Number of pages6
JournalCell Cycle
Volume12
Issue number19
DOIs
StatePublished - 2013
Externally publishedYes

Keywords

  • Cell cycle
  • Cyclin-dependent kinase
  • DNA damage
  • G2 checkpoint
  • MK 1775

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Biology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Wee1 kinase as a target for cancer therapy'. Together they form a unique fingerprint.

Cite this